Abstract
Erlotinib is widely used in the management and treatment of non-small cell lung cancer, pancreatic cancer and several other types of malignancies. It is one of the inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. Ocular side effects are rare compared to cutaneous toxicities which are more common. We are reporting a case of erlotinib induced trichomegaly in a 65-year-old Malay female who is suffering from metastatic adenocarcinoma of the lung. The patient started to notice coarse eyebrows and long eyelashes almost 1 year after initiation of treatment. The length of eyelashes is around 17mm. She was treated conservatively with frequent trimming of eyelashes and eyebrows since she was asymptomatic. Keywords: Epidermal growth factor receptor inhibitors, Erlotinib, Trichomegaly
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
